Could stem cells slow Huntington's? new trial tests cellavita HD

NCT ID NCT03252535

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a stem cell therapy called Cellavita HD in 49 people with Huntington's disease. Participants received either a low dose, high dose, or placebo through IV infusions over several months. The study measured changes in motor skills to see if the treatment could slow the disease's progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Cellavita HD (mesenchymal stem cells)

What this could lead to

If successful, this could point toward a treatment that slows or improves motor decline in Huntington's disease.

What could go wrong

This is a small, early-phase trial with only 49 participants. Results may not be conclusive, and stem cell therapies carry risks like immune reactions or unknown long-term effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.

    Valinhos, São Paulo, 13271-130, Brazil